It’s a tie: Sanofi and Novo come in neck-and-neck at the FDA with two new diabetes combo OKs
Sanofi and Novo Nordisk tried mightily to beat each other to the finish line first with a combination of their long-lasting insulin with their GLP1 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
